{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:17:08Z","timestamp":1761715028615,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","primary-care-diabetes.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Primary Care Diabetes"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.pcd.2016.03.004","type":"journal-article","created":{"date-parts":[[2016,4,22]],"date-time":"2016-04-22T04:04:25Z","timestamp":1461297865000},"page":"360-368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Use of antidepressant medications not associated with A1C among individuals with diabetes in NHANES sample"],"prefix":"10.1016","volume":"10","author":[{"given":"Jamie","family":"Kammer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko S.","family":"Hosler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Leckman-Westin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Gregory","family":"DiRienzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcd.2016.03.004_bib0155","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4088\/JCP.13m08443","article-title":"National trends in long-term use of antidepressant medications: results from the U.S. National Health and Nutrition Examination Survey","volume":"75","author":"Mojtabai","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pcd.2016.03.004_bib0160","series-title":"Antidepressant Use in Persons Aged 12 and Over: United States, 2005\u20132008","first-page":"1","author":"Pratt","year":"2011"},{"key":"10.1016\/j.pcd.2016.03.004_bib0165","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0006-3223(98)00100-0","article-title":"Novel antipsychotics and new onset diabetes","volume":"44","author":"Wirshing","year":"1998","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pcd.2016.03.004_bib0170","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1192\/bjp.bp.107.037184","article-title":"First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis","volume":"192","author":"Smith","year":"2008","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pcd.2016.03.004_bib0175","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/npp.2010.78","article-title":"Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients","volume":"35","author":"Nielsen","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pcd.2016.03.004_bib0180","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1192\/bjp.bp.109.076935","article-title":"Treatment with antipsychotics and the risk of diabetes in clinical practice","volume":"197","author":"Kessing","year":"2010","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pcd.2016.03.004_bib0185","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/ije\/dyv186","article-title":"Commentary: Antidepressants and diabetes risk: why are there discrepant findings from cohort studies based on patient records and those based on serial phenotyping?","volume":"44","author":"Kivimaki","year":"2015","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.pcd.2016.03.004_bib0190","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc07-1827","article-title":"Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program","volume":"31","author":"Rubin","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2016.03.004_bib0195","doi-asserted-by":"crossref","first-page":"228","DOI":"10.4082\/kjfm.2013.34.4.228","article-title":"Antidepressant use and diabetes mellitus risk: a meta-analysis","volume":"34","author":"Yoon","year":"2013","journal-title":"Korean J. Fam. Med."},{"key":"10.1016\/j.pcd.2016.03.004_bib0200","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/YCO.0b013e32835a4206","article-title":"Effects of antidepressants on glucose metabolism and diabetes mellitus type 2 in adults","volume":"26","author":"Deuschle","year":"2013","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.pcd.2016.03.004_bib0205","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1517\/14740338.5.1.157","article-title":"The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms","volume":"5","author":"McIntyre","year":"2006","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.pcd.2016.03.004_bib0210","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.2337\/dc13-0560","article-title":"Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review","volume":"36","author":"Barnard","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2016.03.004_bib0215","doi-asserted-by":"crossref","first-page":"863","DOI":"10.4088\/JCP.v61n1109","article-title":"Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment","volume":"61","author":"Fava","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pcd.2016.03.004_bib0220","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.arcmed.2004.12.018","article-title":"Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients","volume":"36","author":"Gulseren","year":"2005","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.pcd.2016.03.004_bib0225","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2296-4-7","article-title":"Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial","volume":"4","author":"Paile-Hyvarinen","year":"2003","journal-title":"BMC Fam. Pract."},{"key":"10.1016\/j.pcd.2016.03.004_bib0230","first-page":"1307","article-title":"Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial","volume":"11","author":"Kang","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.pcd.2016.03.004_bib0235","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2296-8-34","article-title":"Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: a double-blind randomised placebo controlled 6-month trial","volume":"8","author":"Paile-Hyvarinen","year":"2007","journal-title":"BMC Fam. Pract."},{"key":"10.1016\/j.pcd.2016.03.004_bib0240","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.2337\/dc09-0785","article-title":"Effect of pharmacological treatment of depression on A1C and quality of life in low-income Hispanics and African Americans with diabetes: a randomized, double-blind, placebo-controlled trial","volume":"32","author":"Echeverry","year":"2009","journal-title":"Diabetes Care"},{"year":"2014","series-title":"About the National Health and Nutrition Examination Survey","author":"Centers for Disease Control and Prevention","key":"10.1016\/j.pcd.2016.03.004_bib0245"},{"key":"10.1016\/j.pcd.2016.03.004_bib0250","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1177\/0898264314535635","article-title":"Impact of obesity and physical activity on functional outcomes in the elderly: data from NHANES 2005\u20132010","volume":"26","author":"Vasquez","year":"2014","journal-title":"J. Aging Health"},{"key":"10.1016\/j.pcd.2016.03.004_bib0255","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.pcd.2016.03.004_bib0260","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/brain\/aws009","article-title":"Parkinson's disease, insulin resistance and novel agents of neuroprotection","volume":"136","author":"Aviles-Olmos","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.pcd.2016.03.004_bib0265","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000100369","article-title":"Safety and efficacy of s-citalopram in patients with co-morbid major depression and diabetes mellitus","volume":"54","author":"Amsterdam","year":"2006","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.pcd.2016.03.004_bib0270","doi-asserted-by":"crossref","first-page":"e21551","DOI":"10.1371\/journal.pone.0021551","article-title":"Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials","volume":"6","author":"Ye","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.pcd.2016.03.004_bib0275","doi-asserted-by":"crossref","first-page":"618","DOI":"10.2337\/diacare.23.5.618","article-title":"Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial","volume":"23","author":"Lustman","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2016.03.004_bib0280","first-page":"231","article-title":"Depression treatment and its impact upon the quality of life in patients with diabetes type 2 \u2013 the Croatian study","volume":"22","author":"Filipcic","year":"2010","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.pcd.2016.03.004_bib0285","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/archpsyc.63.5.521","article-title":"Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial","volume":"63","author":"Lustman","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pcd.2016.03.004_bib0290","first-page":"1525","article-title":"The effects of sertraline on blood lipids, glucose, insulin and HBA1C levels: a prospective clinical trial on depressive patients","volume":"16","author":"Kesim","year":"2011","journal-title":"J. Res. Med. Sci."},{"key":"10.1016\/j.pcd.2016.03.004_bib0295","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00006842-199705000-00007","article-title":"Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial","volume":"59","author":"Lustman","year":"1997","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.pcd.2016.03.004_bib0300","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00213-013-2972-5","article-title":"Antidepressant use and glycemic control","volume":"227","author":"Mojtabai","year":"2013","journal-title":"Psychopharmacology (Berl)"}],"container-title":["Primary Care Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991816300031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991816300031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:55:47Z","timestamp":1761695747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1751991816300031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S1751991816300031"],"URL":"https:\/\/doi.org\/10.1016\/j.pcd.2016.03.004","relation":{},"ISSN":["1751-9918"],"issn-type":[{"type":"print","value":"1751-9918"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of antidepressant medications not associated with A1C among individuals with diabetes in NHANES sample","name":"articletitle","label":"Article Title"},{"value":"Primary Care Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcd.2016.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}